
    
      The study will consist of 2 parts involving up to 12 healthy male participants. In Part 1, up
      to 6 participants will receive a single 80 mg dose of [14C]-TAK-385 administered as an oral
      solution. In Part 2, up to 6 participants will receive a single oral 80 mg dose of TAK-385
      administered as two 40 mg tablets and an 80 Î¼g intravenous (into a vein) dose of
      [14C]-TAK-385 (containing not more than 37.0kBq [1000 nCi] 14C).

      This single centre study will take place in the United Kingdom.
    
  